Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional Results available

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

ClinicalTrials.gov ID: NCT04908189

Public ClinicalTrials.gov record NCT04908189. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment

Study identification

NCT ID
NCT04908189
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
729 participants

Conditions and interventions

Interventions

  • Deucravacitinib Drug
  • Placebo Other
  • Apremilast Drug

Drug · Other

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 14, 2021
Primary completion
Feb 5, 2024
Completion
Nov 11, 2026
Last update posted
Jun 12, 2025

2021 – 2026

United States locations

U.S. sites
24
U.S. states
19
U.S. cities
24
Facility City State ZIP Site status
Local Institution - 0149 Mountain Brook Alabama 35223
Local Institution - 0212 Sacramento California 95815
Local Institution - 0188 Whittier California 90602
Local Institution - 0192 Skokie Illinois 60076
Local Institution - 0203 Hopkinsville Kentucky 42240
Local Institution - 0195 Baton Rouge Louisiana 70836
Local Institution - 0169 Cumberland Maryland 21502
Local Institution - 0034 Okemos Michigan 48864
Local Institution - 0133 Eagan Minnesota 55121
Local Institution - 0109 Hattiesburg Mississippi 39402
Local Institution - 0108 New York New York 10003
Local Institution - 0186 Rochester New York 14642
Local Institution - 0196 Charlotte North Carolina 28277
Local Institution - 0180 Cleveland Ohio 44106
Local Institution - 0189 Oklahoma City Oklahoma 73116
Local Institution - 0147 Portland Oregon 97239
Local Institution - 0016 Duncansville Pennsylvania 16635
Local Institution - 0182 Summerville South Carolina 29486
Local Institution - 0167 Lubbock Texas 79424
Local Institution - 0070 Mesquite Texas 75150
Local Institution - 0184 Plano Texas 75024
Local Institution - 0187 Seattle Washington 98122
Local Institution - 0190 Franklin Wisconsin 53132
Local Institution - 0175 Milwaukee Wisconsin 53217

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 114 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04908189, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 12, 2025 · Synced Jul 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04908189 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →